Novo Nordisk and BioLabs Europe invite you to apply for a Golden Ticket. The Golden Ticket provides lab bench and office space for one year at BioLabs Heidelberg or BioLabs Hôtel-Dieu (Paris), and access to the Novo Nordisk team of scientific and industry advisors.
Golden Ticket Benefits
1-year membership, lab bench and office space
to de-risk your technology and scale your business
No strings attached
IP rights belongs to you
Free choice of residency in Heidelberg or Paris, providing the hottest start-up incubator environments in Europe
Mentoring and support
from Novo Nordisk drug discovery and development experts
A buzzing entrepreneur community
and connectivity with organizations and investors in the local innovation ecosystem
Gateway to a
potential future/long term collaboration
with Novo Nordisk
​
What is Novo Nordisk searching for?
Novo Nordisk is looking for early-stage biotech companies that fit the following criteria:
Focused on working on novel drug targets and transformational medicines in cardiometabolic disease, in particular in one of the below stated therapeutic areas.
Quality of the scientific work and impact
Robust research plan and potential for successful development of the research
Initial business and funding strategy
Therapeutic Areas
Diabetes
-
Efficacy beyond blood glucose lowering, e.g. co-morbidity risk reduction
-
Reversal of insulin resistance
-
Prevention of disease progression, e.g. preservation of beta-cell health (T1D/T2D)
Liver Disease (MASH)
-
Fibrosis resolution/inhibition of fibrogenesis
-
Suppression of chronic inflammation
-
Liver regenerative approaches
-
Non-invasive diagnostic biomarkers
Obesity
​
-
Enhancing energy expenditure
-
Modulating hedonic eating behavior (e.g. hedonic and reward signaling)
-
Modulation of the counter-regulatory mechanisms (e.g. metabolic set-point)
Rare Diseases
-
Rare, non-malignant hematologic diseases
-
Rare endocrine diseases
Cardiovascular
Disease
-
Atherosclerotic CVD, HFpEF & cardiomyopathies
-
MoAs providing risk reduction additive to LDL/TG lowering and anti-inflammation
-
Precision-medicine approaches to heart failure
-
Disease-modification (e.g. gene therapy)
Drug Discovery &
Enabling Technology
-
Drug discovery & enabling technology in the previous stated therapeutic areas
Kidney Disease
-
CKD/DKD, polycystic, kidney disease & glomerulonephritis
-
Fibrosis resolution/inhibition of fibrogenesis
-
Preservation of vascular and glomerular integrity
The Application Process
01
Submit applications by
January 20,2025
02
A subset of applications will be identified as semi-finalist and be invited for a virtual pitch around February 7 - 10
03
Winning teams will be selected by February 21, 2025 and will be invited to present their company & scientific concept at the European Investor Day 2025 on March 11, 2025 in Paris
04
Up to 4 awards will be granted
Good luck!
Judging Criteria and Judges
The applications are assessed by a scientific expert panel. Their assessments are based on four evaluation criteria:
Fit to Novo Nordisk’s strategic interest areas
Unmet need to be addressed and how will the product differentiate from existing treatment options
Quality of the scientific data and impact
Research plan robustness and the key milestone to reach within one year
Team competency
Potential to successfully achieve research milestones and program development
Contact us
